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Abstract
Black people are at increased risk of thrombotic thrombocytopenic purpura (TTP). Whether
clinical presentation of TTP in Black patients has specific features is unknown. We
assessed here differences in TTP presentation and outcome between Black andWhite
patients. Clinical presentation was comparable between both ethnic groups. However,
prognosis differed with a lower death rate in Black patients than in White patients (2.7% ver-
sus 11.6%, respectively, P = .04). Ethnicity, increasing age and neurologic involvement
were retained as risk factors for death in a multivariable model (P < .05 all). Sixty-day overall
survival estimated by the Kaplan-Meier curves and compared with the Log-Rank test con-
firmed that Black patients had a better survival than White patients (P = .03). Salvage thera-
pies were similarly performed between both groups, suggesting that disease severity was
comparable. The comparison of HLA-DRB1*11, -DRB1*04 and -DQB1*03 allele frequen-
cies between Black patients and healthy Black individuals revealed no significant differ-
ence. However, the protective allele against TTP, HLA-DRB1*04, was dramatically
decreased in Black individuals in comparison with White individuals. Black people with TTP
may have a better survival than White patients despite a comparable disease severity. A
low natural frequency of HLA-DRB1*04 in Black ethnicity may account for the greater risk
of TTP in this population.
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Introduction
Thrombotic thrombocytopenic purpura (TTP) is a severe form of thrombotic microangiopathy
(TMA) characterized by a profound thrombocytopenia, erythrocyte fragmentation and organ
failure of variable severity. TTP results from an excessive systemic platelet aggregation caused
by a severe deficiency in ADAMTS13, the protease specifically involved in the cleavage of von
Willebrand factor large multimers [1]. In adults, severe ADAMTS13 deficiency results mostly
from polyclonal autoantibodies [2]. These pathophysiological findings account for the efficacy
of plasma-based treatment in TTP, which allows supplying ADAMTS13 deficiency. Immuno-
modulatory drugs aimed at depleting anti-ADAMTS13 antibody-producing B-lymphocytes
are associated to standard treatment in an increasing number of cases [3, 4]. Those therapeutic
strategies allowed improving outstandingly TTP prognosis, with current survival rates of 80–
85% [5]. Despite this significant progress, death still occurs in up to 20% of patients, usually
within the first days of management. Age, cerebral involvement and a very high LDH level
were associated with more death [6]. Moreover, cardiac troponin-I (cTnI) was also strongly
associated with death as well as refractoriness [7, 8].
Black African and Caribbean people are overrepresented in TTP registries [9–12], suggest-
ing the involvement of specific genetic risk factors. In White people, the human leukocyte anti-
gen (HLA) class II DRB111 and DQB103 alleles were found to be genetic risk factors
associated with TTP, whereas HLA DRB104 was found protective [13–16]. Interestingly,
other diseases were also found overrepresented in Black people, such as arterial hypertension,
systemic lupus erythematosus and monoclonal gammopathies. Of note, it was shown that
these diseases may be more severe in Black people than in White people, and may therefore
require a specific management. Moreover, the involved pathophysiological mechanisms may
be distinct from those observed in White people [17–20]. In TTP, works reported possible eth-
nic differences in early outcome; indeed, Black patients with TTP were reported to experience
more exacerbations [21], deserving further investigation. Here, we asked whether TTP pre-
sented with specific clinical presentation, prognosis and HLA-related features according to eth-
nicity. More particularly, we focused on ethnicity as a possible prognostic factor.
Patients and Methods
Study Design
To assess whether TTP had specific characteristics in Black patients, we compared clinical pre-
sentation, outcome and HLA class II DRB111, DRB104 and DQB103 genotyping of TTP in
Black patients (including African and Caribbean patients) to those of White patients. Patients
of both groups were included during the same period of time from October, 2000 (date at
which our registry was set up) to the date of the study design (October, 2013) and studied until
death or durable remission. They were included non-selectively from intensive care units and
departments of Internal medicine, Hematology, and Nephrology in 26 French centers. This
study was approved by our institutional review board in accordance with the Declaration of
Helsinki (CPP Ile-de-France V, Hôpital Saint-Antoine, Paris), and the French Data Protection
Authority (“Commission Nationale Informatique et Libertés”, CNIL, authorization n°911539,
and “Comité consultatif sur le traitement de l’information en matière de recherche dans le
domaine de la santé”, CCTIRS, authorization n°11.537, Paris, France). Written informed con-
sent was obtained from patients studied for HLA typing. For patients not explored for HLA
typing and explored routinely, a verbal consent was obtained and reported in the patient’s
record, in accordance with the local ethical committee.
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Data collection
Each patient’s epidemiologic, clinical and routine biological data were collected by a research
study nurse, as previously reported [22], using a standardized form, and transferred to a com-
puterized database. Cerebral involvement included focal deficiency, seizure, headache, vigi-
lance disturbances (inadequate response) or coma (absence of response). Renal involvement
was assessed by serum creatinine level and the estimated glomerular filtration rate (eGFR) by
the Cockcroft method. ADAMTS13 activity and the search of anti-ADAMTS13 antibodies
were performed as previously described [23].
Patients and Treatment
All adult patients with features of microangiopathy associated with a severe acquired
ADAMTS13 deficiency (< 10% of normal activity) and no other cause for cytopenias (cancer,
chemotherapy or drug, transplantation, HIV infection) were enrolled. To avoid the influence
of inadequate plasma volumes in survival and to focus on the prognostic value of patient char-
acteristics on diagnosis, we excluded patients who were not managed according to standard
recommendations [4, 11, 24]. Complete response, durable remission, exacerbations and
relapses were previously defined [4]. In case of disease exacerbation or relapse, daily TPE was
resumed, in association with rituximab as a second-line treatment [4]. Patients without features
of active infection received steroids (1 mg/kg/d for 3 weeks).
HLA typing
All patients samples were referred to the National reference Center for the exploration of HLA
system (Laboratoire d'Immunologie et d'Histocompatibilité, Hôpital Saint-Louis, Paris,
France). Allele frequencies of African patients were compared to those of healthy people origi-
nating from Burkina-Faso, Nigeria, Cameroun, Senegal, Guinee-Bissau and Mali. All Carib-
bean patients originated fromMartinique and Guadeloupe islands. Allele frequencies of
Caribbean patients were compared to those of healthy people from Martinique.
Given the limited number of patients with available DNA samples in the present study, we
specifically assessed allele frequencies of HLA-DRB111, DRB104 and DQB103. HLA
DRB111, DRB104 and DQB103 medium resolution typings were performed as previously
detailed [14].
Statistical Analysis
Quantitative variables were summarized by median (range) and compared by the Wilcoxon
rank-sum test; categorical data was summarized as count (%) and compared by the chi-squared
test or Fisher's exact test. Overall survival between both ethnic groups was estimated by the
Kaplan-Meier curves and compared with the Log-Rank test. Findings were considered statisti-
cally significant at P-values< 0.05. Risk factors of early mortality were investigated by logistic
regression. A univariable analysis was first carried out, and variables associated with mortality
at the P< .20 level were included in a backward multivariable analysis. Only variables associ-
ated at the .05 level were kept in the final model.
HLA DRB111, DRB104 and DQB103 allelic frequencies were compared by Fisher exact
test. Odds ratio (OR) was calculated for each risk factor and given with its 95% Fisher’s exact
confidence intervals. A Wilcoxon rank-sum test was used to compare continuous variables.
Only variables associated at a level< .05 were kept in the final model. SPSS v15 software was
used for analysis.
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Results
1. Study group
From the considered study period, the Registry included 3400 adult patients with a diagnosis of
TMA and available data. Among them, 420 were considered as having a TTP with an acquired/
autoimmune severe ADAMTS13 deficiency fulfilling all inclusion criteria of the study; all were
followed during at least 30 days after treatment initiation. Two hundred and twenty-four
patients were White and 74 others were Black. The 122 remaining patients were of a different
ethnic origin or of undetermined ethnic origin and were not included in the present study.
Twenty-eight patients from the 298 included here died during the 30-day period of observa-
tion, corresponding to a death rate of 9.4% (95% CI [8%-15%]). The other patients were dis-
charged alive.
2. Univariate analysis
Table 1 details clinical and biological characteristics of patients on diagnosis, treatment and
outcome according to ethnicity. Clinical presentation and biological features on diagnosis were
comparable between both groups. Particularly, age, cerebral involvement, LDH and cTnI levels
were comparable, providing evidence that disease severity on diagnosis was comparable
between Black andWhite patients. Steroids use, time to platelet count recovery and plasma vol-
ume required to achieve a durable complete remission were also comparable, and salvage
Table 1. Clinical characteristics of patients on diagnosis and outcome according to ethnicity.
Black patients* White patients P-value
(N = 74) (N = 224)
Age (years) 33 (26.2–49) 37 (27–49) 0.25
Sex (female) 57 (77) 149 (66.5) 0.12
Neurologic involvement 54 (73) 136 (60.7) 0.08
Hemoglobin level (g/dL) 7.35 (6.5–8.75) 7.7 (6.5–9.1) 0.95
Reticulocyte count (x109/L) 169 (107–261) 169.6 (106–267) 0.30
Platelet count (x109/L) 15.5 (8–23.7) 14 (9–21) 0.77
LDH level (IU/L) 5.75 (3.5–8.4) 4.89 (3–7) 0.15
Serum creatinine level (μmol/L) 101 (75–142) 91 (74.7–126) 0.18
Cardiac troponin Ic 0.25 μg/L 40%1 48%2 0.45
ANA (IU/mL) 33 (50.8) 115 (52.5) 0.92
Anti-dsDNA antibodies (IU/mL) 4 (12.5%) 20 (9.5) 0.53
Plasma volume (L/kg) 519 (277–1100) 599 (319–1044) 0.93
Steroids 68 (92%) 192 (86%) 0.23
Rituximab 31 (42%) 86 (38%) 0.58
Time to platelet count recovery (days) 16 (6–28.5) 18 (8–29) 0.26
Flare-up 39 (55) 113 (50.4) 0.6
Relapse 17 (23.6) 59 (26.3) 0.76
Mortality 2 (2.7) 26 (11.6) 0.04
Abbreviations: ANA: antinuclear antibodies. dsDNA: double-stranded deoxyribonucleic acid.
*Included Black Africans and Caribbeans.
1performed on 35
254 patients.
Quantitative values are expressed in median (range) and compared by the Wilcoxon rank-sum test. Qualitative values are expressed as total number (%)
and compared by the chi-squared test. P<0.05 was considered statistically signiﬁcant.
doi:10.1371/journal.pone.0156679.t001
Prognostic Impact of Ethnicity in TTP
PLOSONE | DOI:10.1371/journal.pone.0156679 July 6, 2016 4 / 10
therapies including rituximab (Table 1) were equally introduced in association with TPE. The
number of flare-up episodes and relapse rate were also comparable. However, death rate was
significantly lower in Black patients than in White patients. Indeed, only 2 Black patients died
(2.7%) of multivisceral failure versus 26 in the White patients group (11.6%) (P = .04)
(Table 1). This result was confirmed by calculation of 60-day overall survival estimated by the
Kaplan-Meier curves and compared with the Log-Rank test (Fig 1). Black patients had a better
survival than White patients (P = .03).
3. Multivariate analysis
Variables tested for inclusion in the model were ethnicity, age, neurologic involvement, LDH
level, platelet count and serum creatinine level. Although cardiac cTnI assessment was per-
formed randomly (as detailed in [8]), not all patients were explored, so this parameter could
not be included in our model. Finally, ethnicity, increasing age and neurologic involvement
were retained as risk factors in the multivariable model (OR = 0.2, 95% CI = 0.03–0.74;
OR = 1.56, 95% CI = 1.19–2.6; OR = 3.43, 95% CI = 1.2–12.4, respectively, P< .05 for all)
(Table 2).
4. Human leukocyte antigen allele frequencies
The HLA alleles DRB111, DRB104 and DQB103 were studied in 26 African patients origi-
nating from 7 countries of West Africa, and 24 Caribbean patients. Accurate allele frequencies
for HLA-DQB103 were not available for healthy individuals of Mali, Senegal and Guinea.
Allele frequencies of HLA-DRB111, -DRB104 and -DQB103 between TTP patients and
healthy individuals within Black ethnicity was comparable in all conditions (Tables A to C in
S1 File). We also compared allele frequencies of HLA-DRB111, -DRB104 and -DQB103
Fig 1. Kaplan-Meier survival estimates of overall survival in patients with TTP as a function of ethnicity (Black
patients, n = 74; White patients, n = 224). Survival in both groups was compared with the Kaplan-Meier estimator.
doi:10.1371/journal.pone.0156679.g001
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alleles between Black individuals (patients and healthy people) and healthy White individuals.
Interestingly, we observed that HLA-DRB111 allele frequency in Black people was comparable
(Nigeria, Cameroon, Burkina-Faso) or increased (Mali, Senegal, Guinea) when compared to
this observed in White people, whereas HLA-DQB103 allele frequency was comparable
between both ethnic groups. More interestingly, the protective allele against autoimmune TTP,
HLA-DRB104, was dramatically decreased in Black individuals (in TTP patients but also in
healthy individuals) in comparison with White individuals (Table 3; Tables D and E in S1 File;
http://www.allelefrequencies.net).
Discussion
We report in this work that clinical presentation of autoimmune TTP was comparable between
Black and White people. Response to treatment was also comparable for time to remission,
exacerbation and relapse rate. However, we found that death rate was 4 times lower in Black
people, with only two fatal outcomes in this group, including one patient with multiple risk
Table 2. Multivariate analysis.
OR P-value
Black ethnicity 0.2 0.03
Age 1.56 0.002
Neurologic involvement 3.43 0.03
Platelet count 0.99 0.67
LDH 1.06 0.09
Serum creatinine level (per 25 μmol/L) 1.03 0.62
OR: Odd-ratio. LDH: lactate dehydrogenase. P<0.05 was considered statistically signiﬁcant.
doi:10.1371/journal.pone.0156679.t002
Table 3. Comparison of HLA-DRB1*04 allele frequencies between Black andWhite populations.
HLA DRB1*04 allele
n Frequency* P-value OR (95% CI)
Healthy individuals (White, N = 172) 48 0.16
Autoimmune TTP (Africans, N = 26) 1 0.019 0.006 0.10 (0.0025–0.67)
Healthy individuals origin
Nigeria (N = 258) 3 0.006 5.6x10-18 32.7 (0.006–0.098)
Cameroon (N = 126) 2 0.01 8x10-11 24 (6.01–206)
Burkina-Faso (N = 53) 0 0 5.2x10-7 -
Mali (N = 49) 4 0.04 0.004 4.33 (1.46–17.5)
Senegal (N = 112) 17 0.078 0.014 2.15 (1.13–4.27)
Guinea (N = 65) 10 0.077 0.06 2.12 (0.97–5)
Autoimmune TTP (Caribbeans, N = 24) 2 0.042 0.04 4.23 (0.98–38.5)
Healthy individuals origin
Martinique (N = 100) 22 0.11 0.31
HLA: human leukocyte antigen. OR: Odds ratio. CI: conﬁdence interval. TTP: thrombotic thrombocytopenic purpura. N: total number of patients. n: number of
patients bearing the allele.
*Allele frequency was calculated by dividing the number of patients bearing the allele with total number of alleles.
Comparison of phenotypic frequencies between both groups was performed using a 2-tailed Fisher exact test. P<0.05 was considered statistically
signiﬁcant.
doi:10.1371/journal.pone.0156679.t003
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factors of death (an old age, cerebral manifestations, an LDH level of 9.8 times the upper nor-
mal value and a cTnI level> 0.25 μg/L). Interestingly, despite this remarkable difference in
death rate, disease severity was comparable between both groups; indeed, prognosis on diagno-
sis (including age, the prevalence of cerebral involvement, serum concentrations of LDH and
cTnI) was comparable and salvage therapies were equally used in both ethnic groups. From
these statements, one could hypothesize that Black people are more resistant to microthrombi-
induced organ ischemia. Our results provide the first evidence that Black ethnicity, in addition
to age and neurologic involvement is independently associated to survival.
This result was unexpected in this context since other vascular diseases such as arterial
hypertension and malignant hypertension are of worse prognosis in Black people [25]. More-
over, Black people were reported to display physiologically higher levels of vWF than White
people with, consequently, a lower ADAMTS13 activity [26]. However, one could hypothesize
that in Black people this proagregant state is counterbalanced by other physiological mecha-
nisms such as a more efficient fibrinolysis or a more efficient cleavage of vWF by alternative
proteolytic pathways [27, 28], which may at least in part account for the better prognosis of
TTP in Black people. In this work, we found that exacerbations were comparable between both
ethnic groups, which is in contrast with a previous report that reported more exacerbation in
African Americans [21]. However, this apparent discrepancy may be explained at least in part
by different therapeutic modalities between both studies, which may have impacted on early
outcome; indeed, TPE were usually interrupted progressively after remission achievement in
one study, and immediately after remission achievement in the other. Moreover, a significant
number of patients of one study received cyclosporine A.
Black people are more at risk of developing autoimmune TTP [9–11]. So far however,
genetic risk factors involved in the occurrence of anti-ADAMTS13 antibodies in Black people
are unknown. In White people, DRB111 and DQB103 alleles of the class II HLA system were
identified as genetic risk factors of autoimmune TTP, whereas HLA DRB104 was found pro-
tective [13–16]. In this work, our results bring two conclusions. The first is that among Black
individuals, there is no over-representation of DRB111 and DQB103 loci nor under-repre-
sentation of DRB104 in patients with autoimmune TTP, suggesting additional risk factors for
autoimmunity in Black people that remain to be discovered. The second, is the dramatically
low natural frequency of the protective allele DRB104 in this ethnic group. This finding may
therefore represent a strong risk factor for the development of autoimmune TTP in Black peo-
ple, accounting for the over-representation of Black people in TTP registries. The reasons for
which DRB104 is a protective allele for autoimmune TTP is still unknown. Recently, it was
shown that DRB111 molecule recognizes CUB2 domain-derived peptides from ADAMTS13
with a higher efficiency than other HLA molecules [29], which may account for the increased
occurrence of autoimmune TTP in patients harboring this HLA molecule. In the same manner,
one could hypothesize that DRB104 could recognize ADAMTS13 epitopes with a poorer effi-
ciency than the other HLA molecules, which may protect patients harboring this molecule
from the disease.
Patients of our registry were managed homogeneously according to a written protocol
based on previous studies and in accordance with international guidelines [4]. Therefore, we
believe our results are robust. However, a major limitation of our study is the low number of
events that were analyzed for some endpoints. This limitation is a general issue in TTP as it is a
rare disease; it is also inherent in the questions raised by our work that led us to assess rare
events (mortality and uncommon HLA alleles) in specific subgroups of patients. Consequently,
our results need to be confirmed by other groups.
In conclusion, Black ethnicity may represent an independent prognostic factor associated
with survival in TTP. Further studies from a larger number of patients are now needed to
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account for this observation. A low natural frequency of HLA-DRB104 in Black ethnicity may
account for the greater risk of autoimmune TTP in this population, and studies are required to
understand the protective mechanisms of this molecule.
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